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1. INTRODUCTION 
Developing a new vaccine takes, on average, ten years.1  In the case of COVID-19, 
however, the pharmaceutical industry developed vaccines in a matter of months, and three 
quickly received emergency use authorization.2 As discussed in the chapters by Sachs, Ouellette, 
Price, and Sherkow, among others in this volume, this record-breaking pace of development 
raised concerns regarding rare undetected side effects or ones that would manifest only in the 
long-term.    
This chapter argues that the potential for vaccine-related harms raises acute concerns for 
vulnerable populations.  These harms have a disparate impact on low-income people, who are 
disproportionately non-White, and who have limited financial resources to obtain medical care, 
weather job losses, and pursue injury compensation. When a vaccine is given as a 
countermeasure during a declared public health emergency (PHE), the problem is acute because 
of the limited availability of injury compensation.  
The chapter reviews and assesses the two existing mechanisms to which injured parties 
can turn for a remedy:  1) the National Vaccine Injury Compensation Program (VICP), which 
applies to most vaccines given in the U.S. and, 2) the far less generous and less accessible 
Countermeasures Injury Compensation Program (CICP), which applies to vaccinations given as 
countermeasures3 during PHEs.  It highlights the health and financial disparities suffered by 
 
† This chapter is based in part on Katharine Van Tassel, Carmel Shachar & Sharona Hoffman, Covid-19 Vaccine 
Injuries — Preventing Inequities in Compensation, 384 NEW ENG. J. MED. ___ (2021). 
* Visiting Professor of Law, Case Western Reserve University School of Law, Cleveland, Ohio. 
** Edgar A. Hahn Professor of Law and Professor of Bioethics, Co-Director of Law-Medicine Center, Case Western 
Reserve University School of Law, Cleveland, Ohio. 
1 The College of Physicians of Philadelphia, The History of Vaccines: Vaccine Development, Testing, and 
Regulation, HISTORYOFVACCINES.ORG, https://www.historyofvaccines.org/content/articles/vaccine-development-
testing-and-regulation (last updated Jan. 17, 2018).  
2 U.S. Food & Drug Administration, FDA Takes Additional Action in Fight Against COVID-19 by Issuing 
Emergency Use Authorization for Second COVID-19 Vaccine (Dec. 18, 2020), https://www.fda.gov/news-
events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-
authorization-second-covid; Jen Christensen, Johnson & Johnson's Covid-19 Vaccine Gets Emergency Use 
Authorization From FDA, CNN (February 27, 2021), available at https://www.cnn.com/2021/02/27/health/johnson-
johnson-covid-19-vaccine-fda-eua/index.html.  
3 A countermeasure is defined as a “vaccination, medication, device, or other item recommended to diagnose, 
prevent or treat a declared pandemic, epidemic or security threat.”  Health Resources and Services Administration, 
Countermeasures Injury Compensation Program (CICP), https://www.hrsa.gov/cicp (last reviewed Nov. 2020).  
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vulnerable populations during a pandemic and its aftermath and how these disparities are 
intensified by the CICP.  The chapter then develops a proposal for legal reform to the injury 
compensation and vaccine approval processes that aims to protect the disadvantaged and enhance 
equity.   
2. VACCINE SIDE EFFECTS 
During the COVID-19 pandemic, Pfizer/BioNTech and Moderna enrolled 44,000 and 
30,000 subjects, respectively, in the studies upon which they relied to obtain initial Emergency 
Use Approval (“EUA”) from the Food & Drug Administration (“FDA”).4 With tens of thousands 
of trial participants, common side effects that occur fairly soon after vaccination were identified.5 
But there was little opportunity to identify adverse events that might appear in the longer term or 
that are rare enough that they would be discovered only after a significant percentage of the 
public is vaccinated.  Such side effects could include joint pain, anaphylaxis, and neurological 
conditions like encephalitis, transverse myelitis, or Guillain-Barré Syndrome, which are known 
to occur with other vaccines.6  
A case in point is the National Swine Flu Immunization Program. In 1976, the federal 
government decided to protect the public from Swine Flu and quickly advanced the 
administration of a vaccine. Forty million vaccines were given in just a few months. 
Unfortunately, 450 vaccinated people developed Guillain-Barré Syndrome, a rare and serious 
neurological disorder that can result in muscle weakness and paralysis.7 The program was 
quickly suspended, but the harm was done.  Unfortunately, it triggered an enduring public 
mistrust of flu vaccinations and often appears as part of the narrative of the anti-vaccination 
movement.8 
3. VACCINE INJURY COMPENSATION PROGRAMS  
The United States is fortunate to have a robust system to compensate individuals who 
suffer vaccine injuries. This system, however, is not available to those vaccinated with a 
countermeasure during a declared PHE.  
 
4 Denise Grady & Katie Thomas, Moderna and Pfizer Reveal Secret Blueprints for Coronavirus Vaccine Trials, NY 
TIMES (Sept. 17, 2020), https://www.nytimes.com/2020/09/17/health/covid-moderna-vaccine.html. 
5 Helen Branswell, A Side-by-Side Comparison of the Pfizer/BioNTech and Moderna Vaccines, STAT NEWS (Dec. 
19, 2020), https://www.statnews.com/2020/12/19/a-side-by-side-comparison-of-the-pfizer-biontech-and-moderna-
vaccines/. 
6  Health Resources and Services Administration, Vaccine Injury Table, 
https://www.hrsa.gov/sites/default/files/hrsa/vaccine-compensation/vaccine-injury-table.pdf (accessed Jan. 5, 2021).  
For example, the possibility that the AstraZenica and Johnson & Johnson vaccines could cause extremely rare, life-
threatening blood clots was not discovered until millions of people had been vaccinated. Angela Dewan, et. al, 
Here's What To Know About The Risk Of Blood Clots And The AstraZeneca Vaccine, CNN (April 3, 2021), 
available at https://www.cnn.com/2021/04/02/health/astrazeneca-blood-clots-explainer-intl-cmd-gbr/index.html; 
Anne Flaherty, Rare Reactions to Johnson & Johnson Vaccine Remain A Mystery, Putting Many Women On Edge, 
ABC NEWS (April 17, 2021), available at https://abcnews.go.com/Politics/rare-reactions-johnson-johnson-vaccine-
remain-mystery-putting/story?id=77092178. 





3.1 The VICP 
The National Vaccine Injury Compensation Program (VICP) is normally available to 
anyone who is injured by a vaccine after the FDA  approves it and the Centers for Disease 
Control and Prevention (CDC) recommends it for children or pregnant women.9  The VICP 
covers the majority of vaccines administered in the United States. This no-fault program was 
created in the 1980s to ensure relatively quick and fair compensation for vaccine injuries and to 
insulate manufacturers from liability as an incentive for them to pursue vaccine development.10 
Claimants who develop recognized symptoms of injuries listed in the Vaccine Injury Table 
within a certain amount of time after vaccination need not prove that the injuries were caused by 
the vaccine.  Rather, they present evidence only about the extent of their damages.11 When an 
injury is not listed in the Vaccine Injury Table, petitioners must prove that it was caused or 
exacerbated by the vaccine. 12 Claim denials can be appealed to the Federal Court of Claims.13  
The VICP offers up to $250,000 for pain, suffering, and emotional distress14 as well as 
attorneys’ fees and legal expenses to good faith claimants.15 As of the end of 2020, the Vaccine 
Injury Compensation Trust Fund (“VICTF”) was valued at over $4 billion.16 The VICTF is 
funded by a $.75 excise tax on each vaccine dose that is paid by the manufacturers.17   From 
 
9 Health Resources and Services Administration, Covered Vaccines, https://www.hrsa.gov/vaccine-
compensation/covered-vaccines/index.html (last reviewed Dec. 2020).     
10 Health Resources and Services Administration, About the National Vaccine Injury Compensation Program, 
https://www.hrsa.gov/vaccine-compensation/about/index.html (last reviewed Dec. 2020) [hereinafter About VICP]; 
Health Resources and Services Administration, National Vaccine Injury Compensation Program, 
https://www.hrsa.gov/vaccine-compensation/index.html  (last reviewed Nov. 2020). 
11 Health Resources and Services Administration, Who Can File a Petition?, https://www.hrsa.gov/vaccine-
compensation/eligible/index.html (last reviewed Dec. 2020); HEALTH RESOURCES AND SERVICES ADMINISTRATION, 
WHAT YOU NEED TO KNOW ABOUT THE NATIONAL VACCINE INJURY COMPENSATION PROGRAM (VICP) 8 (April 
2019), https://www.hrsa.gov/sites/default/files/hrsa/vaccine-compensation/resources/about-vaccine-injury-
compensation-program-booklet.pdf.    
12 The Office of Special Masters, United States Court of Federal Claims, Guidelines for Practice Under the National 
Vaccine Injury Compensation Program, 47 (2020), https://www.uscfc.uscourts.gov/sites/default/files/Guidelines-
4.24.2020.pdf. 
13 Id. 
14 HEALTH RESOURCES AND SERVICES ADMINISTRATION, supra note 11, at 12. 
15 Health Resources and Services Administration, How to File a Petition, https://www.hrsa.gov/vaccine-
compensation/how-to-file/index.html (last reviewed December 2020).  Prior to 2017, the average time to resolve a 
VICP case was 575 days, or approximately 1.5 years. In 2017, HHS adopted a Final Rule that added Shoulder Injury 
Related to Vaccine Administration (“SIRVA”) injuries to the Vaccine Injury Table. SIRVA injuries are injuries 
related to the intramuscular injection of a vaccine. Adding these SIRVA claims “dramatically” increased the number 
of claims filed in the VICP.  Since 2017, the average amount of time for a VICP case to finally resolve has increased 
significantly to 751 days, or approximately 2 years.  National Vaccine Injury Compensation Program: Revisions to 
the Vaccine Injury Table, 85 Fed. Reg. 43794 (proposed July 20, 2020) (to be codified at 42 C.F.R. pt. 100), 
available at https://www.federalregister.gov/documents/2020/07/20/2020-15673/national-vaccine-injury-
compensation-program-revisions-to-the-vaccine-injury-table. 
16 National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table, supra note 6.  
17 About VICP, supra note 10 (clarifying that “Trivalent influenza vaccine … is taxed $.75 because it prevents one 
disease; measles-mumps-rubella vaccine, which prevents three diseases, is taxed $2.25”). 
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2006 through 2018, the VICP has approved about 70% of claims.18  Since 2015, the fund has 
paid out an average of $216 million per year to an average of 615 claimants per year. 19  
3.2 The CICP  
The same benefits are not available to people injured by vaccines given as 
countermeasures during a declared PHE.20  The Department of Health and Human Services’ 
declaration of a PHE triggers the Public Readiness and Emergency Preparedness (PREP) Act.21 
This federal law requires that claimants bring claims relating to countermeasures that are used 
during a PHE only under the Countermeasures Injury Compensation Program (CICP).22 Such 
countermeasures include not only vaccines, but also drugs, equipment, and more.   CICP awards 
are paid by the Covered Countermeasure Process Fund (“CCPF”).  Congress funds the CCPF 
through emergency appropriations to HHS that HHS may transfer to the CCPF. 23 Manufacturers 
do not contribute to this fund as they do to the VICTF. 
 
18 Ken Alltucker, Consumers Filed 106 Injury Claims From COVID-19 Vaccines, Ventilators and 
Hydroxychloroquine. Here's Why None Have Been Paid, USA TODAY (March 28, 2021), available at 
https://www.usatoday.com/story/news/health/2021/03/28/covid-19-vaccines-hydroxychloroquine-generate-dozens-
injury-claims/6995509002/. 
19 Tom Hals, COVID-19 Era Highlights U.S. 'Black Hole' Compensation Fund for Pandemic Vaccine Injuries, 
REUTERS (Aug. 21, 2020), https://www.reuters.com/article/us-health-coronavirus-vaccines-liability/covid-19-era-
highlights-u-s-black-hole-compensation-fund-for-pandemic-vaccine-injuries-idUSKBN25H1E8.  
20 CONGRESSIONAL RESEARCH SERVICE, THE PREP ACT AND COVID-19: LIMITING LIABILITY FOR MEDICAL 
COUNTERMEASURES (Sept. 21, 2020), https://crsreports.congress.gov/product/pdf/LSB/LSB10443.  
21 42 U.S.C.A. § 247d-6d (2010). 
22 Congressional Research Service, supra note 20.  
23 Congressional Research Service, supra note 20. Both the CARES Act and the Coronavirus Preparedness and 
Response Supplemental Appropriations Act (CPRSA) appropriate funding that HHS may use for the Covered 
Countermeasure Process Fund. CPRSA appropriates $3.1 billion to the Secretary to respond to COVID-19, 
including the development and purchase of countermeasures and vaccines, while allowing these funds to ‘be 
transferred to, and merged with’ the Covered Countermeasure Process Fund. Similarly, the CARES Act appropriates 
$27 billion to the Secretary for similar purposes, again providing that the Secretary may transfer these funds to the 
Covered Countermeasure Process Fund.” Id. 
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The CICP is far less generous than the VICP.24  It compensates people only for serious 
injuries,25 requires a heightened burden of proof regarding injury causation,26 and has a one-year 
statute of limitations following the date of vaccination. 27  Individuals are bound by the one-year 
filing deadline regardless of when their symptoms appear or are determined to be associated with 
the vaccine.  Furthermore, the deadline applies to pregnant women who must file claims on 
behalf of their babies within one year of being themselves vaccinated, leaving parents with only 
a few, short months to discover any injuries after their baby is born..28  The CICP also limits 
damages awards.29  For example, under the CICP, claimants can recover a maximum of only 
$50,000 in lost income for each year out of work. The CICP also denies any compensation for 
pain, suffering and emotional distress as well as for attorney’s fees and costs.30 There is no 
opportunity to appeal claim denials.31  
Furthermore, the CICP process for pursuing compensation is lengthier, more difficult, 
and more expensive because of the absence of reimbursement for attorneys’ fees and costs.32 It is 
important to note that those receiving countermeasure vaccines during a declared PHE can never 
pursue injury claims under the VICP, even if their symptoms appear or are linked to the vaccine 
 
24 Health Resources and Services Administration, Comparison of Countermeasures Injury Compensation Program 
(CICP) to the National Vaccine Injury Compensation Program (VICP), https://www.hrsa.gov/cicp/cicp-vicp (last 
reviewed Nov. 2020). 
25 Serious injuries are generally those that warrant hospitalization or lead to a significant disability, loss of function, 
or death. 42 C.F.R. § 110.3(z). One of the most common injuries caused by all vaccines, including COVID-19 
vaccines, which are not likely to be viewed as “serious” and will not warrant compensation under the CICP are 
Shoulder Injury Related to Vaccine Administration (“SIRVA”) injuries. National Vaccine Injury Compensation 
Program: Revisions to the Vaccine Injury Table, supra note 16. SIRVA injuries are injuries related to the 
intramuscular injection of a vaccine. Id. The costs associated with these shoulder injuries can be significant as these 
injuries can prevent those whose jobs involve lifting from being able to work for, potentially, long periods of time. 
Examples of positions that involve lifting include nurses, nursing aids, grocery workers, meat processors, fire 
fighters, and custodial staff, just to name a few. Many of these front-line positions are filled by people from low-
income and minority populations. The CICP’s narrow compensation scheme results in these workers being left to 
bear the cost of the losses associated with these SIRVA injuries as they will never be compensated for these injuries 
if they were vaccinated during the PHE.   
26 Determinations of causation must be “based on compelling, reliable, valid, medical and scientific evidence.” 42 
U.S.C. § 247d–6e(b)(4). 
27 42 C.F.R. § 110.42.  
28 42 C.F.R. § 110.3(n)(1)(3); Countermeasures Injury Compensation Program (CICP): Administrative 
Implementation, Interim Final Rule, 75 Fed. Reg. 63666 (Oct. 15, 2010) (codified at 42 C.F.R. pt. 110) (corrected 
by Countermeasures Injury Compensation Program (CICP): Administrative Implementation, Interim Final Rule, 758 
Fed. Reg. 64955 (Oct. 21, 2010), https://www.federalregister.gov/documents/2010/10/15/2010-
25110/countermeasures-injury-compensation-program-cicp-administrative-implementation-interim-final-rule.  
29 HEALTH RESOURCES AND SERVICES ADMINISTRATION, COUNTERMEASURES INJURY COMPENSATION PROGRAM 
REQUEST FOR BENEFITS FORM INSTRUCTIONS 1-2 (updated Mar. 2020),  
https://www.hrsa.gov/sites/default/files/hrsa/cicp/cicp-request-form-instructions.pdf. 
30 Health Resources and Services Administration, About CICP, https://www.hrsa.gov/cicp/about (last reviewed Nov. 
2020); Nicholas M. Pace et al., COVID-19 Vaccine Campaign Must Include Fair Compensation for Side Effects, 
THE HILL (Dec. 17, 2020), https://thehill.com/opinion/healthcare/530546-the-compensation-system-for-potential-
side-effects-is-an-important-part-of.  
31 42 U.S.C. § 247d–6d(b)(5)(C). 
32 See supra text associated with notes 29-30. 
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after the declaration is lifted.33  If they were vaccinated while a PHE emergency declaration was 
in place, they are forever barred from the VICP with respect to the injection in question. 
The CICP was first implemented in 2010.34  Up until 2020 and the declared COVID-19 
PHE,  the CICP received 485 claims (mostly related to the H1N1 vaccine) but awarded 
compensation to only 39 people, for a total of $5.7 million.35  While the VICP has a 70% 
payment rate for claims filed from 2006 through 2018, the CICP has rejected 90% of injury 
claims since it was created. 36 As of the end of March 2021, 106 COVID-19-related claims were 
filed with the CICP.37 One-half of the claims were for vaccines, with the remainder relating to 
hydroxychloroquine and other COVID-19 treatments.38 
4. PREP ACT TRADEOFFS 
PREP Act immunity for all countermeasures is designed to accomplish two main goals. 
First, this immunity encourages manufacturers to speed innovative treatments to market during a 
declared PHE when there are no other viable treatments. Manufacturers are more willing to skip 
the usual time it takes to invest in safety through testing when they are given immunity from 
liability.  
Second, PREP Act immunity is an attempt to manage the risk that quickly designed and 
produced countermeasures might cause a large number of injuries. At the same time that 
manufacturers are being encouraged to forego their usual testing protocols, the PHE is driving 
the FDA to speed the temporary licensure of countermeasures using a lower standard of safety 
and effectiveness through its fast–track Emergency Use Approval process.39 Together, these 
measures hold the potential to increase the number and seriousness of any unintended 
countermeasure injuries. 
The trade-offs that are the centerpiece of the PREP Act may make some sense for most 
countermeasures, but they do not appear to do so for vaccines. First, countermeasures that hold 
the greatest potential to cause injuries are treatments such as drugs and devices. Drugs and 
devices, such as antiviral drugs or ventilators, will be used to treat those who have fallen ill from 
 
33 Countermeasures Injury Compensation Program (CICP): Administrative Implementation, Interim Final Rule, 75 
Fed. Reg. at 63,666.  
34 Health Resources and Services Administration, HHS Sets Regulations to Implement Countermeasures Injury 
Compensation Program (Oct. 15, 2010), https://www.hrsa.gov/about/news/press-releases/2010-10-15-cicp.html.  
35 Tom Hals, COVID-19 Era Highlights U.S. 'Black Hole' Compensation Fund for Pandemic Vaccine Injuries, 
REUTERS (Aug. 21, 2020), https://www.reuters.com/article/us-health-coronavirus-vaccines-liability/covid-19-era-
highlights-u-s-black-hole-compensation-fund-for-pandemic-vaccine-injuries-idUSKBN25H1E8.  
36 Alltucker, supra note 18.  
37 Id.  
38 Id.  
39 Under section 564(a)(1) of the Federal Food, Drug, and Cosmetic Act, the FDA can issue an Emergency Use 
Approval when the product may be effective in diagnosing, treating, or preventing the disease or condition, the 
known and potential benefits outweigh the known and potential risks, and there is no adequate, approved, and 
available alternative to the product for diagnosing, treating, or preventing such disease or condition. Guidance for 
Industry, Emergency Use Authorization of Medical Products and Related Authorities, 82 FR 4362 (January 13, 




the pandemic-triggering disease. The manufacturers of these countermeasures have no immunity 
absent the PREP Act. Consequently, granting these manufacturers immunity to encourage their 
speed to market while providing sick consumers with quick access to possible treatments 
provides a positive tradeoff for consumers for the loss of access to compensation for all but the 
most serious of injuries. 
In contrast, vaccines fall into a different category as preventatives. First, the target 
population for vaccines are healthy people. As such, there is no ‘access to treatment’ benefit for 
this population that provides a trade-off for withholding compensation for injuries. Second, in 
the context of vaccines, there already is a system, the VICP, that, in the absence of the PREP 
Act, offers immunity to manufacturers to encourage speed to market while adequately 
compensating all people who are injured by a vaccine.  It is simply unethical to severely limit 
compensation for healthy consumers who are injured after agreeing to be vaccinated with an 
experimental vaccine.  They often do so not only for their own benefit, but also for the good of 
society to promote herd immunity. 
5. VULNERABLE POPULATIONS AND THE VACCINE INJURY COMPENSATION PROBLEM 
People are less likely to obtain compensation for injuries arising from vaccines they 
received as countermeasures during a declared PHE than they are for injuries associated with 
vaccines included in the VICP. Furthermore, the CICP process for pursuing compensation is 
more  burdensome.40 Those receiving countermeasure vaccines during a declared PHE can never 
pursue injury claims under the VICP, even if their symptoms appear or are linked to the vaccine 
after the declaration is lifted.41 
 These concerns  are particularly acute for  low-income people and people of color 
because these groups typically endure the greatest difficulties during public health disasters and 
their aftermaths. During the COVID-19 pandemic, racial and ethnic minorities suffered a death 
rate that was more than double that of White people.42  Likewise, infection rates were 
significantly higher in economically disadvantaged areas than in wealthier ones.43  Similar 
patterns were evident in past disasters, such as the 1918 Spanish influenza pandemic.44 
Vaccinating members of minority and low-income populations should therefore be a high 
priority. 
5.1 Vaccine Hesitancy and Lack of Access to Compensation  
 
40 See supra text associated with notes 29-30. 
41 Countermeasures Injury Compensation Program (CICP): Administrative Implementation, Interim Final Rule, 75 
Fed. Reg. at 63,666.  
42 NATIONAL URBAN LEAGUE, STATE OF BLACK AMERICA UNMASKED: 2020 EXECUTIVE SUMMARY 12, 
http://sobadev.iamempowered.com/sites/soba.iamempowered.com/files/NUL-SOBA-2020-ES-web.pdf (accessed 
Dec. 30, 2020); Dylan Scott & Christina Animashaun, COVID-19’s Stunningly Unequal Death Toll in America, in 
One Chart, VOX (Oct. 2, 2020), https://www.vox.com/coronavirus-covid19/2020/10/2/21496884/us-covid-19-
deaths-by-race-black-white-americans.  
43 Phillip Reese, High-Poverty Neighborhoods Bear the Brunt of COVID’s Scourge, KAISER HEALTH NEWS (Dec. 
15, 2020), https://khn.org/news/article/high-poverty-neighborhoods-bear-the-brunt-of-covids-scourge/.   
44 Clare Bambra et al., The COVID-19 Pandemic and Health Inequalities, 74 J. EPIDEMIOLOGY COMMUNITY 
HEALTH 964, 964 (2020).   
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At the same time, however, there are high levels of vaccine skepticism and reluctance in poor 
and minority communities.45  In some cases, vaccine hesitancy may stem from longstanding 
inequities in medical treatment and abuses that have resulted in general mistrust of government.   
A well-known example is the infamous Tuskegee Study.46  In this study, which spanned from 
1932 until 1972, researchers deprived African American men of penicillin for syphilis, without 
informing them that a cure was available, because they wanted to study the natural course of the 
disease.47   
In a Kaiser Family Foundation poll conducted in August and September 2020, 49% of Black 
respondents stated that they would probably not or definitely not accept a COVID-19 vaccine, 
compared to 33% of White respondents.48 Similarly, a Pew Research Center poll conducted in 
November 2020 revealed that while 71% of Black respondents knew someone who had been 
hospitalized or died because of COVID-19, only 42% planned to obtain a COVID-19 vaccine.49     
 During 2021, overall hesitancy dropped as more information was gathered regarding the 
effectiveness and safety of the COVID-19 vaccines.50 However, hesitancy continued to be a 
significant concern among all groups.51 If the media begins to cover stories of individuals who 
were injured but not adequately compensated, such hesitancy may intensify.  As the Presidential 
Commission for the Study of Bioethical Issues pointed out in the context of clinical trials 
generally, people may be more willing to participate in research if assured that they will be 
compensated if injured. 52 Similarly, people may be more willing to participate in mass 
vaccination programs if they know they will be taken care of in the event that they are harmed. 
On the other hand, knowing that they will not get compensated may discourage participation. 
5.2 Compensation Inequities and Structural Racism 
 After an emergency declaration is lifted, newly vaccinated individuals can be eligible for 
VICP compensation if the CDC has recommended the vaccine for routine administration to 
 
45 Shadim Hussain, We Need ‘Horizontal’ Trust to Overcome Vaccine Skepticism, WIRED (Nov. 21, 2020), 
https://www.wired.com/story/we-need-horizontal-trust-to-overcome-vaccine-skepticism/. 
46 Rueben C. Warren et al., Trustworthiness Before Trust — COVID-19 Vaccine Trials and the Black Community, 
383 NEW ENG. J. MED. e121, e121 (2020). 
47 Centers for Disease Control and Prevention, The Tuskegee Timeline, https://www.cdc.gov/tuskegee/timeline.htm 
(last reviewed Mar. 2, 2020). 
48 Liz Hamel et al. Race, Health, and COVID-19: The Views and Experiences of Black Americans, KAISER FAMILY 
FOUNDATION 17 (Oct. 2020), http://files.kff.org/attachment/Report-Race-Health-and-COVID-19-The-Views-and-
Experiences-of-Black-Americans.pdf.  
49 Cary Funk and Alec Tyson, Intent to Get a COVID-19 Vaccine Rises to 60% as Confidence in Research and 
Development Process Increases, PEW RESEARCH CENTER 6, 8 (Dec. 2020), 
https://www.pewresearch.org/science/wp-content/uploads/sites/16/2020/12/PS_2020.12.03_covid19-vaccine-
intent_REPORT.pdf.  
50 Kaiser study March 30, 2021.  
51 Reuters Staff, COVID-19 Vaccine Hesitancy Among Black Americans Drops – Poll (March 30, 2021), available 
at https://www.reuters.com/article/us-health-coronavirus-vaccine-hesitancy-idUSKBN2BM0WY.  
52 The Presidential Commission for the Study of Bioethical Issues, Moral Science: Protecting Participants in 






children or pregnant women.53  However, delaying vaccination until the end of a declared PHE  
can be particularly dangerous for minority and lower-income workers, including many “essential 
workers.”  Many suffer from chronic conditions, such as asthma, heart disease, and diabetes, that 
make it more likely that they will suffer more severely from infectious diseases.54 In addition, 
those with a lower socioeconomic status often have the highest risk of infection because they 
come in close contact with others at work, while taking public transportation, or while living in 
crowded households.   In fact, employees working in person may have no choice as to whether to 
receive a vaccine once it is available.  Employers may require workers to obtain vaccines, and 
the U.S. Equal Employment Opportunity Commission has determined that such employer 
mandates are lawful.55 
At the same time, low-income people who most need to be vaccinated are the most 
financially at-risk.  A serious vaccine injury could thus be catastrophic for them if they are not 
appropriately compensated.  Having access only to the CICP rather than the VICP can thus have 
a disproportionate adverse impact on poor communities.  
 By contrast, the people who can afford to wait for vaccination until an emergency 
declaration has ended, triggering VICP availability, will tend to be more privileged. This group 
will probably consist largely of people who can work remotely and socially isolate until they feel 
confident about the vaccine’s safety profile. They tend to be disproportionately well-educated, 
high earners, and White.56  If those with socioeconomic advantages choose to wait for vaccines 
while their working-class counterparts cannot, they may be compensated far more liberally for 
the same types of vaccine injuries. Differences between the VICP and CICP could therefore 
reinforce long-established inequities rooted in income, race, and ethnic identity.  
6. PROPOSALS FOR LEGAL REFORM 
We argue that anyone who receives a vaccine that is a countermeasure to a PHE  should 
have immediate access to the VICP. Disadvantaged people with the greatest need for 
vaccination, who are also the most at-risk of financial harm, should benefit from an efficient and 
fair system of injury compensation. Moreover, penalizing early recipients of vaccines could 
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undermine the important public health goal of vaccinating as many people as possible as quickly 
as possible to achieve herd immunity.   
Experts predict that the world will face future global pandemics, and many have long 
worried about bioterrorism attacks.57 Establishing the correct incentives and relief mechanisms 
for people who receive vaccinations is therefore of critical importance.  
6.1 Amending the PREP Act 
A straight-forward modification to address the inequities that the CICP propagates is to 
amend the PREP Act.  Under this approach, lawmakers would establish that all vaccines that the 
FDA approves and the CDC recommends to ameliorate a PHE will be covered by the VICP, 
regardless of whether they are to be administered to pregnant women or children.58 This would 
include vaccines receiving an emergency use authorization (EUA).59   
The carve-out would not impact any other countermeasures, such as drugs and devices, 
that have an EUA. Injury claims related to those countermeasures would still be submitted to the 
CICP.  The vaccine carve-out is justified because vaccines are given to healthy people in part for 
the good of society to protect the collective.  By contrast, drugs and devices approved under an 
EUA are provided to unhealthy individuals to treat and cure their individual maladies.    
The second element of this proposal is that Congress should require manufacturers to pay 
a 75-cent excise tax per dose for all vaccines that the FDA approves and that the CDC 
recommends as PHE countermeasures. This excise tax will serve to ensure that the Vaccine 
Injury Compensation Trust Fund is adequately financed.  As noted above, such a tax already 
applies to vaccines included in the VICP.60   During a PHE, when the government purchases 
vaccines and then distributes them to the public without charge, part of this purchase price can be 
allocated to cover the excise tax, This will provide immediate funding for the VICP to cover any 
increase in the number of claims.  In addition, Congress should expand the number of special 
masters who handle VICP cases because this docket is likely to grow significantly.61  This 
measure will ensure that claims will be processed expeditiously. 
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7. CONCLUSION 
Even the most carefully developed and tested vaccine can lead to injuries.  Such injuries 
can disproportionately affect vulnerable populations who are most in need of vaccinations but 
are also at risk of financial ruin if harmed by a vaccine. Fortunately, injured parties can usually 
attain appropriate recovery through the generous and accessible VICP.  However, during a 
declared PHE, individuals receiving vaccines that are countermeasures can turn only to the much 
less robust CICP if injured.   
This difference is not simply technical.  It can have severe ramifications, especially for 
disadvantaged populations.  In some cases, people in high-risk communities may struggle to 
decide whether they should forego a vaccine and risk becoming infected or risk a vaccine injury 
for which they could receive little if any compensation. 
The chapter has proposed legal changes to rectify this wrong.  It argues that the PREP 
Act should be amended to ensure  that relevant vaccines are covered by the VICP rather than the 
CICP.  Rendering the VICP available to all injured parties, including members of vulnerable 
communities, would advance multiple goals.  It would promote public health by encouraging the 
public to pursue early vaccination, enhance equity, and increase the likelihood of adequate relief 
in all injury cases.    
 
 
